Every material Form 8-K Damora Therapeutics, Inc. has filed with the SEC since April 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026, after stockholders approved it at a February 9, 2026 special meeting. The company says the move does not change its business, management, obligations, assets or liabilities, and its shares continue to trade on Nasdaq under the symbol DMRA, now under a new CUSIP. The filing states that certain shareholder rights changed as a result, so holders should review the Cayman articles.
Redomestication effective July 16, 2026; stockholders approved it at a February 9, 2026 special meeting.
Ordinary shares began trading under new CUSIP G2646Y104 at the open on July 20, 2026; Nasdaq symbol remains DMRA.
Cayman memorandum and articles of association now govern the company in place of its Delaware charter and bylaws; certain shareholder rights changed.
Directors and executive officers entered into new indemnification agreements on July 16, 2026.
Damora Therapeutics said its Chief Financial Officer, Lori Firmani, ceased serving in that role effective May 1, 2026. Brian Burkavage, the company's Senior Vice President, Finance, was appointed principal financial officer and principal accounting officer at the same time. Firmani's separation benefits are conditional on her signing a separation agreement and general release.
Firmani's departure took effect May 1, 2026; the Board decided on April 28, 2026.
Firmani's separation benefits include a $6,000 health savings account contribution and full acceleration of her outstanding equity awards, subject to a release of claims.
Burkavage joined Damora in December 2025 and previously served as Senior Vice President, Finance and Chief Accounting Officer at IO Biotech, Inc. from November 2021 to December 2025.
On April 17, 2026, Damora Therapeutics' Audit Committee dismissed EY Denmark as its independent registered public accounting firm and engaged Ernst & Young LLP, effective immediately. The filing states there were no disagreements or reportable events with EY Denmark, but EY Denmark's report on the fiscal 2024 financial statements included a going concern explanatory paragraph.
Dismissal and new engagement both dated April 17, 2026; EY Denmark had served as auditor since 2019.
EY Denmark's reports for fiscal 2025 and 2024 had no adverse opinion or disclaimer; the 2024 report contained a going concern explanatory paragraph.
The filing reports no disagreements or reportable events with EY Denmark during fiscal 2024, fiscal 2025 and the interim period through April 17, 2026.
EY Denmark's letter to the SEC dated April 17, 2026 is filed as Exhibit 16.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Damora Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →